Fundraising FoxVesselon
Norwalk, US · Founded 2012 · Delaware corporation
Find your way into Vesselon
Sign up to find every way you can get introduced to Vesselon
- Your email: who you already know at Vesselon, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Vesselon team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
VesselOn is a drug development company using a platform to create enhanced versions of monoclonal antibodies, small molecules, cytokines, proteins, and other therapeutic conjugates, with initial focus on improving anti-PD-1 cancer drugs such as Keytruda. It works in the biopharmaceutical and oncology space to produce proprietary drug candidates.
Founders & leadership
RL
Rhodemann LiExecutive
CT
Clayton T LarsenPresident and Chief Executive Officer; Director
CL
Clay LarsenPresident and Chief Executive Officer; Director
Board
KK
Kevin KimberlinBoard director
PS
Paul S. Latchford, Jr.Board director
JR
Jurgen RathsBoard director
JC
Jon C SerbousekBoard director
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 4 rounds · 2014–2016
▶$250KraisedAug 2016 · 3 investors · BiotechnologyRule 506(b)
▶$250KraisedAug 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rhodemann LiExecutive Officer, Director
- Jon SerbousekDirector
- Paul LatchfordDirector
- Jurgen RathsDirector
- Clay LarsenExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $250K
- Minimum investment
- $25K
- Proceeds to insiders
- $100K
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$75KraisedJul 2016 · 1 investors · BiotechnologyRule 506(b)
▶$75KraisedJul 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul LatchfordDirector
- Jon SerbousekDirector
- Rhodemann LiExecutive Officer, Director
- Jurgen RathsDirector
- Clay LarsenExecutive Officer, Director
- Offering amount
- $150K
- Amount sold
- $75K
- Minimum investment
- $75K
- Proceeds to insiders
- $30K
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$1MraisedJun 2015 · 11 investors · BiotechnologyRule 506(c)
▶$1MraisedJun 2015 · 11 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Paul S. Latchford, Jr.Director
- Jurgen RathsDirector
- Rhodemann LiExecutive Officer, Director
- Clayton T LarsenExecutive Officer, Director
- Jon C SerbousekDirector
- Offering amount
- $4M
- Amount sold
- $1M
- Minimum investment
- $50K
- Sales commissions
- $33.2K
- Proceeds to insiders
- $112K
- Placement agents
- Spencer Trask Ventures, Inc.
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06c
▶$100KraisedJul 2014 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedJul 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Clay LarsenExecutive Officer, Director
- Rhodemann LiExecutive Officer, Director
- Kevin KimberlinDirector
- Offering amount
- $200K
- Amount sold
- $100K
- Minimum investment
- $50K
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
VerseonVerseon uses quantum physics-based modeling combined with AI to design novel small-molecule drug candidates for major human diseases. Its pipeline targets conditions including cardiovascular disease (anticoagulants), diabetic vision loss, multidrug-resistant cancers, and solid-tumor metastasis, with candidates ranging from preclinical to clinical stages.
Regeneron NASDAQ: REGN www.regeneron.comRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
DendreonDendreon develops and manufactures cellular immunotherapies, including PROVENGE (sipuleucel-T), an FDA-approved cellular immunotherapy for prostate cancer patients. The company also provides cell therapy research, development, and contract manufacturing services to other companies bringing cellular therapies to market.
Palleon PharmaceuticalsPalleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms. The company serves patients with conditions including systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune disorders.
Lexicon PharmaceuticalsLexicon Pharmaceuticals develops and commercializes pharmaceutical products, including the marketed drug INPEFA and drug candidates in clinical development such as sotagliflozin, pilavapadin, and LX9851, serving patients in need of treatments across various therapeutic areas.
GeronGeron is a biopharmaceutical company focused on developing therapies for blood cancer. The company has over 30 years of experience in research and clinical development.
NovoronNovoron develops lipoprotein-receptor small molecule therapies aimed at repairing damage and degeneration of the brain and spinal cord, including treatments for proteinopathies and neuroregeneration following traumatic injury. The company focuses on drug discovery for neurological conditions such as neurodegeneration and cognitive decline.
Companies working in the same space as Vesselon.
Frequently asked questions
- What does Vesselon do?
- VesselOn is a drug development company using a platform to create enhanced versions of monoclonal antibodies, small molecules, cytokines, proteins, and other therapeutic conjugates, with initial focus on improving anti-PD-1 cancer drugs such as Keytruda. It works in the biopharmaceutical and oncology space to produce proprietary drug candidates.
- How much funding has Vesselon raised?
- Vesselon has disclosed $1.4M raised across 4 rounds.
- Where is Vesselon headquartered?
- Vesselon is headquartered in Norwalk, US.